Cargando…
Anti‐KIT monoclonal antibody CDX‐0159 induces profound and durable mast cell suppression in a healthy volunteer study
BACKGROUND: Mast cells (MC) are powerful inflammatory immune sentinel cells that drive numerous allergic, inflammatory, and pruritic disorders when activated. MC‐targeted therapies are approved in several disorders, yet many patients have limited benefit suggesting the need for approaches that more...
Autores principales: | Alvarado, Diego, Maurer, Marcus, Gedrich, Richard, Seibel, Scott B., Murphy, Michael B., Crew, Linda, Goldstein, Joel, Crocker, Andrea, Vitale, Laura A., Morani, Pamela A., Thomas, Lawrence J., Hawthorne, Thomas R., Keler, Tibor, Young, Diane, Crowley, Elizabeth, Kankam, Martin, Heath‐Chiozzi, Margo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544977/ https://www.ncbi.nlm.nih.gov/pubmed/35184297 http://dx.doi.org/10.1111/all.15262 |
Ejemplares similares
-
PA01.59. Evaluation of rasayana effect of vayasthapana drugs
por: Ganeshwar Reddy, D Vijay, et al.
Publicado: (2012) -
Targeting KIT on innate immune cells enhances the antitumor activity of checkpoint inhibitors in vivo
por: Gedrich, Richard, et al.
Publicado: (2015) -
Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022) -
Mesure magnetique des dipoles EPA types MBW 0158 et MBW 0159
por: Suberlucq, G, et al.
Publicado: (1985) -
Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy
por: Vitale, Laura A., et al.
Publicado: (2020)